key: cord-304946-fs02dxg5 authors: Brochez, L.; Baurain, J.F.; Del Marmol, V.; Nikkels, A.; Kruse, V.; Sales, F.; Stas, M.; Van Laethem, A.; Garmyn, M. title: Recommendations for skin cancer consultation and surgery during COVID‐19 pandemic date: 2020-08-12 journal: J Eur Acad Dermatol Venereol DOI: 10.1111/jdv.16772 sha: doc_id: 304946 cord_uid: fs02dxg5 nan As a result of the outbreak of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and government lockdown measures, healthcare systems were challenged worldwide. Medical doctors were faced with prioritization of non-COVID19 medical problems in order to reduce potential exposures and to mobilize staff and resources for COVID-19 care. On the other hand, decreases in some non-COVID19 health problems have been observed, e.g. myocardial infarction, newly diagnosed cancers among which esp. skin cancer, . . . and there is concern that delay in these may negatively affect patient outcome. [1] [2] [3] In this respect, it is important to define and communicate recommendations on prioritization of non-COVID19 related health care. In this position paper, we describe recommendations developed by the Belgian Association of Dermato-Oncology (BADO) for prioritization of patients in the field of dermato-oncology during COVID19 pandemic without compromising quality of care and safety. BADO was founded in 2012, and the board consists of a mix of derrmatologists, oncologists and surgeons. Its main goals are to promote multidisciplinary approach of dermato-oncology, to exchange scientific knowledge about dermato-oncology and to work on treatment recommendations for different skin cancer types. These (COVID-19) recommendations are based on estimated potentially harmful effects by delaying a specific consultation type as also discussed in the letter of Tejera-Vaquerizo. 1 We categorized dermato-oncology care into urgent (no delay), semi-urgent (delay for max 8-12 weeks) and low priority (more than 12 weeks delay acceptable) (Tables 1-3 ). In addition, measures for limiting viral transmission during consultation and surgery are described (Tables 4-6 ). In conclusion, the COVID-19 outbreak posed significant challenges to medical staff to offer optimal and timely care in non-COVID19 health problems at the same time keeping the risk of COVID19 spread as low as possible. In the last months, proposals for triage in several health conditions have been published especially in oncology including skin cancer. 4-9 BADO developed recommendations to prioritize dermato-oncological care on a national level in Belgium. In the circumstances of the COVID19 pandemic, the approval and refunding of tele/videoconsultations by the government was accelerated but for skin cancer treatment and follow-up teleconsultations are often suboptimal. 10, 11 These recommendations were needed to take on a nationwide similar approach for the different indications in dermato-oncology; it was also a way to monitor replanning of postponed consultations since acceptable delay period was defined for different indications in dermato-oncology. Because of the fast changing situation, the introduction of the guidelines mentions that 'these recommendations could serve as a guidance and are based on a general weighing of pros/cons. They need to be tuned according to the evolving situation and advices for COVID19 by the government and the weighing of the pros/cons for the individual patient'. For the moment, the lockdown measures in Belgium have been gradually decreased and care has returned to (nearly) normal levels taking into account basic preventive measures • Follow-up actinic keratosis Table 4 Practical planning of the consultation • Consider teleconsultation whenever possible. • This is especially important in patients at risk for serious COVID19 infection (e.g. old ageimmunosuppressive R/other comorbidities) • Prior to consultation, ask the patient: a if he/she has has (had) any fever-or cough-or flu-like symptoms b to bring a face mask if he/she has one Table 5 General precautions during the consultation • Patients should be spaced at least 1.5 m apart while waiting. • Patient should clean their hands with soap and water for at least 20 s. Alternatively they can be asked to use alcohol 70% desinfectant • If patients have a face mask (or the dermatology practice can provide one) they should be asked to wear it. • Patients with fever-or cough-or flu-like symptoms in the past 4 weeks or patients who tested COVID19 positive should wear a face mask up to 30 days after the start of their first symptoms/ positive COVID-19 PCR testing. • The dermatologist who performs a total body examination with dermoscopy should wear a face mask and wash/desinfect hands. The dermatologist can consider to wear gloves during examination. • The dermatoscope should be desinfected with an 70% alcohol solution. The use of a protective cap or polyvinyl chloride (PVC) food wrap on the dermatoscope should be considered. An alcohol solution or gel can be used as interface medium for dermoscopy 12 • Dermoscopy at certain sites like the area under the face mask should be avoided as much as possible 12 Table 6 Precautions during surgery Patient wears face mask Doctor wears face mask and gloves and normal surgical clothing When in the face outside the face mask area sterile field protects as much as possible mask area; normal protective clothing (mask, gloves, surgical clothing) 2. Outpatient intervention in mask area of the face COVID testing (SWAB screening day before) negative If testing is not available, treat the patients as potentially positive and increase doctor's protection: (FFP2) mask and extra protection (e.g. shield and extra surgical apron over surgical clothing) Consider COVID testing in all patients prior to hospitalization The Covid-19 pandemic and the incidence of acute myocardial infarction Fewer cancer diagnoses during the COVID-19 epidemic in the Netherlands Estimated effect of COVID-19 lockdown on melanoma thickness and prognosis: a rate of growth model Skin cancer triage and management during COVID-19 pandemic Managing urology consultations during COVID-19 pandemic: application of a structured care pathway Anti-cancer therapy and clinical trial considerations for gynecologic oncology patients during the COVID-19 pandemic crisis ESMO management and treatment adapted recommendations in the COVID-19 era: breast cancer Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the COVID-19 pandemic Recommendations on management of the SARS-CoV-2 coronavirus pandemic (Covid-19) in kidney transplant patients The role of telemedicine in the delivery of healthcare in the COVID-19 Pandemic Will Teledermatology be the silver lining during and after COVID-19? Art of performing dermoscopy during the times of coronavirus disease (COVID-19): simple change in approach can save the day!